Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05831579 · ClinicalTrials.gov registry record · NA
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
A NA study of Metastatic Cancer and Unresectable Solid Tumor, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05831579: Recruiting NA study of Metastatic Cancer and Unresectable Solid Tumor, sponsored by Washington University School of Medicine.
NCT05831579 is a NA study of Metastatic Cancer and Unresectable Solid Tumor that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 24 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05831579, a NA study of Metastatic Cancer and Unresectable Solid Tumor, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys" throughout the target volume. Standard palliative radiotherapy regimens provide limited durability of response, and there are challenges with delivery to large tumors or in previously irradiated fields. In this study, Proton GRID radiotherapy will be used to deliver three-fraction palliative radiotherapy to patients with tumors needing palliative radiation. The safety and efficacy of this approach will be assessed. It is hypothesized that GRID is highly effective, immunogenic, and associated with low rates of toxicity.
Primary Outcome
-Grade per CTCAE v5.0.
Conditions Studied
Interventions
- RADIATION Proton GRID Radiotherapy
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-05-12 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05831579 shows while recruiting
NCT05831579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Proton GRID Radiotherapy is the first listed.
NCT05831579 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05831579 about?
NCT05831579 is a clinical study titled "Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy". Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys" throughout the target volume. Standard palliative radiotherapy regimens provi...
What is the current status of trial NCT05831579?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2023-05-12. Estimated completion is 2027-06-30.
What conditions does trial NCT05831579 study?
This clinical trial studies the following conditions: Metastatic Cancer, Unresectable Solid Tumor.
What interventions are being tested in trial NCT05831579?
The interventions under investigation include: Proton GRID Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT05831579?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05831579 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05831579's enrollment target sits among peer trials
24 91st of 109 higher than 18 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
RECRUITING · NA
-
Comparison of Whole Body DWI to FDG PET
RECRUITING · NA
-
COBRA: Cancer, Older Adults, Balance and Resistance Activities
RECRUITING · NA
-
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI